Remarkably, evaluation of the premalignant molecular landscape of 212 patients who later developed AML in the Women's Health Initiative cohort found that all subjects with mutations in TP53 and IDH1, and IDH2 eventually developed AML during follow‐up (median time: 9.6 years) [4]. The gene discussed is TP53; the disease is acute myeloid leukemia.